Estronex Profile - Urine

Assess Risk for Estrogen Sensitive Cancers The Estronex Profile measures six important estrogen metabolites and their ratios to help women, and even men, assess whether he or she is at risk of developing estrogen sensitive cancers. Estrogen sensitive cancers include uterine, ovarian, cervical, prostate, and even head and neck cancers. According to the American Cancer Society, an estimated 207,090 new cases of invasive breast cancer are expected to occur among women in the US during 2010; about 1,970 new cases are expected in men. Avoid chances of becoming a statistic and assess estrogen levels and decrease risk with the Estronex Profile. The Estronex Profile measures six important estrogen metabolites, and ratios, including: The "Good" Estrogen 2-hydroxyestrone (2-OHE1) - high levels of 2-OHE1 are ideal to reduce cancer growth. 2-hydroxyestradiol (2-OHE2) - shown to exhibit anti-carcinogenic effects. 2-methoxyestrone (2-OMeE1) - OMeE1 has shown to have anticancer effects and is ideal in high levels. 4-methoxyestrone (4-OMeE1) - as a non-cancerous metabolite, OMeE1 generally does not require treatment at high levels in the body. The "Bad" Estrogen 4-hydroxyestrone (4-OHE1) - considered a "bad" estrogen, 4-OHE1 levels should be low, as high levels may react negatively with damaged DNA. 16-á-hydroxyestrone (16á-OHE1) - also considered a "bad" estrogen, 16á-OHE1 in high levels may encourage tumor development. The Ratios 2-OHE:16á-OHE1 (2:16 ratio) - 2:16 ratios less than 2.0 indicate increasing long-term risk for breast, cervical, and other estrogen sensitive cancers. Importantly, nutritional interventions can help raise Estronex 2:16 ratios and decrease long-term risk. Studies also indicate that this risk is modifiable! 2-OHE1:2-OMeE1 - a high level of 2-OHE1:2-OMeE1 may also indicate imbalanced estrogen metabolism and low activity in the COMT gene. Evaluation of methylation activity is recommended. Advantages of the Estronex Profile: An easy-to-collect first-morning urine specimen; no blood draw is necessary! Cost-effective method to assess estrogen metabolism allowing clinicians to retest often to monitor therapy in patients. Easy to incorporate into a breast cancer prevention program. Ideal for men to evaluate risk of breast and prostate cancer. **Not for sale to NY Residents